HIV vaccine


SAB-185 Polyclonal Antibody Graduates to Phase 3 The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the […]

ACTG Announces Graduation of Novel Polyclonal Antibody Therapy SAB-185 to ...